American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Arcus Biosciences, Inc. (RCUS)

$17.76 -4.21% NYSE: RCUS · 15-min delayed

HAYWARD, California
Public · NYSE: RCUS
601 employees
Founded 2015

Visit website Follow

$3.6BMarket cap

$33.0MRevenue · FY2025

-$353.0MNet income

601Employees

RCUSNYSE

2018IPO

About Arcus Biosciences, Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Founded: 2015
Type: Public · NYSE: RCUS
Employees: 601
IPO date: Mar 15, 2018
Headquarters: 3928 POINT EDEN WAY
HAYWARD, California 94545
Phone: (510) 694-6200
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: RCUS NYSE
SEC CIK: 1724521
LEI: 549300I1AHR8KMMFIS52
EIN: 473898435
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Arcus Biosciences, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/arcus-biosciences-inc/"><img src="https://americancompanies.com/badge/arcus-biosciences-inc.svg" alt="Arcus Biosciences, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Arcus Biosciences, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $33.0M
Net income: -$353.0M
Total assets: $1.1B
Market cap: $3.6B

Source: SEC EDGAR · updated Jun 7, 2026

NYSE: RCUS

$17.76 -4.21%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$12.37 $31.57

52-week range

Market cap: $3.6B
Shares outstanding: 201.3M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Mar 15, 2018

Arcus Biosciences, Inc. (RCUS) Stock Price

Reported a net loss of $353.0M in FY2025.
Trading 44% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Arcus Biosciences, Inc..

Write a review

Newsroom

News about Arcus Biosciences, Inc.

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? Zacks Investment Research · 2026-10-21 · neutral Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks Investment Research · 2026-10-21 · negative An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run The Motley Fool · 2026-07-13 · neutral Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend Benzinga · 2024-12-02 · positive Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033 GlobeNewswire Inc. · 2024-08-23 · positive Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences - Arcus Biosciences (NYSE:RCUS) - Benzinga Benzinga · 2024-07-08 · neutral

News & sentiment via Polygon.io

FAQ

Arcus Biosciences, Inc.: frequently asked questions

Is Arcus Biosciences, Inc. an American company?

Arcus Biosciences, Inc. is a US-based company headquartered in Hayward, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Arcus Biosciences, Inc. headquartered?

Arcus Biosciences, Inc. is headquartered in Hayward, California, United States.

Is Arcus Biosciences, Inc. publicly traded?

Yes — Arcus Biosciences, Inc. is a publicly traded company. Its stock trades under the ticker symbol RCUS on the NYSE.

What does Arcus Biosciences, Inc. do?

Arcus Biosciences, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

When was Arcus Biosciences, Inc. founded?

Arcus Biosciences, Inc. was founded in 2015.

Explore